RecruitingNCT06988605
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Sponsor
Galderma R&D
Enrollment
1,000 participants
Start Date
Jul 14, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Eligibility
Min Age: 12 Years
Inclusion Criteria3
- Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
- Adolescent and adult participants aged >=12 years with moderate-to-severe AD.
- Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.
Exclusion Criteria4
- Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
- Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
- Participants who received nemolizumab previously.
- Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(108)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06988605
Related Trials
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
NCT0700342545 locations
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
NCT0729080343 locations
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT0727766050 locations
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT050422581 location